Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading uniQure N.V. chart...

About the Company

uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

Exchange

NASDAQ

Website

uniqure.com

$3M

Total Revenue

588

Employees

$259M

Market Capitalization

-0.94

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $QURE News

uniQure NV QURE

4d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

uniQure NV (QURE) Reports 2023 Financial Results Amid Strategic Reorganization

1mon ago, source: Yahoo Finance

Cash Position: uniQure NV (NASDAQ:QURE) reported a robust cash reserve of approximately $618 million as of December 31, 2023, expected to fund operations into Q2 2027. Revenue: Revenue for 2023 ...

uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates

26d ago, source: Yahoo Finance

It's been a sad week for uniQure N.V. (NASDAQ:QURE), who've watched their investment drop 12% to US$5.59 in the week since the company reported its annual result. The results were mixed overall ...

QURE uniQure N.V.

3d ago, source: Seeking Alpha

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

3d ago, source: ADVFN

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated interim data including up to 30 ...

Maintaining Hold on uniQure: Balancing Long-Term Potential Against Near-Term Uncertainties

28d ago, source: Business Insider

Begin your TipRanks Premium journey today. uniQure (QURE) Company Description: uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to ...

uniQure NV CEO Matthew Kapusta Sells 27,904 Shares

29d ago, source: Yahoo Finance

uniQure NV (NASDAQ:QURE), a company specializing in gene therapy, has reported a significant insider transaction. CEO and Managing Director Matthew Kapusta sold 27,904 shares of the company on ...

uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

3d ago, source: ADVFN

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Walid Abi-Saab ...

QURE uniQure N.V.

13d ago, source: Seeking Alpha

The chart has 1 X axis displaying Time. Data ranges from 2021-12-30 21:00:00 to 2033-12-30 21:00:00. The chart has 1 Y axis displaying values. Data ranges from -6.460890767 to 7.040788732.

uniQure NV (QURE) Reports 2023 Financial Results Amid Strategic Reorganization

1mon ago, source: Yahoo Finance

Cash Position: uniQure NV (NASDAQ:QURE) reported a robust cash reserve of approximately $618 million as of December 31, 2023, expected to fund operations into Q2 2027. Revenue: Revenue for 2023 ...

uniQure N.V. (QURE)

23d ago, source: Yahoo Finance

It's been a sad week for uniQure N.V. ( NASDAQ:QURE ), who've watched their investment drop 12% to US$5.59 in the week ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...